Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403812 · ClinicalTrials.gov registry record · NA
Assessing DCog Short for Neurotoxicity in CAR-T
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07403812: Clinical Trial NA study, sponsored by Beth Israel Deaconess Medical Center.
NCT07403812 is a NA study that has not yet begun recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07403812, a NA study, has not yet begun recruiting, sponsored by Beth Israel Deaconess Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
Primary Outcome
Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to detect neurotoxicity on or before the onset of clinically confirmed ICANS. Sensitivity is defined as the proportion of patients with clinically confirmed ICANS for whom DCog Short indicates neurotoxicity on or before
Interventions
- BEHAVIORAL DCog Short
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What is known before NCT07403812 opens enrollment
NCT07403812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which DCog Short is the first listed.
NCT07403812 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07403812 about?
NCT07403812 is a clinical study titled "Assessing DCog Short for Neurotoxicity in CAR-T". The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.
What is the current status of trial NCT07403812?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-07. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07403812?
The interventions under investigation include: DCog Short (BEHAVIORAL).
Who is sponsoring clinical trial NCT07403812?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07403812's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia